{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:36:04Z","timestamp":1761708964956},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,4,15]],"date-time":"2014-04-15T00:00:00Z","timestamp":1397520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12035-014-8691-z","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T05:18:09Z","timestamp":1397452689000},"page":"43-56","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer\u2019s Disease: Prophylactic and Therapeutic Applications"],"prefix":"10.1007","volume":"51","author":[{"given":"Jinghong","family":"Kou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Eun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinandan","family":"Pattanayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Planque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhir","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichiro","family":"Fukuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,15]]},"reference":[{"key":"8691_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/ng0106-11","volume":"38","author":"J Hardy","year":"2006","unstructured":"Hardy J (2006) Amyloid double trouble. Nat Genet 38:11\u201312","journal-title":"Nat Genet"},{"key":"8691_CR2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173\u2013177","journal-title":"Nature"},{"key":"8691_CR3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","volume":"408","author":"C Janus","year":"2000","unstructured":"Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J et al (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease. Nature 408:979\u2013982","journal-title":"Nature"},{"key":"8691_CR4","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D et al (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease. Nature 408:982\u2013985","journal-title":"Nature"},{"key":"8691_CR5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/415462a","volume":"415","author":"E Check","year":"2002","unstructured":"Check E (2002) Nerve inflammation halts trial for Alzheimer\u2019s drug. Nature 415:462","journal-title":"Nature"},{"key":"8691_CR6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46\u201354","journal-title":"Neurology"},{"key":"8691_CR7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0197-4580(02)00124-0","volume":"23","author":"EM Sigurdsson","year":"2002","unstructured":"Sigurdsson EM, Wisniewski T, Frangione B (2002) A safer vaccine for Alzheimer\u2019s disease? Neurobiol Aging 23:1001\u20131008","journal-title":"Neurobiol Aging"},{"key":"8691_CR8","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/nm783","volume":"8","author":"C Hock","year":"2002","unstructured":"Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM (2002) Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8:1270\u20131275","journal-title":"Nat Med"},{"key":"8691_CR9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","volume":"64","author":"AJ Bayer","year":"2005","unstructured":"Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64:94\u2013101","journal-title":"Neurology"},{"key":"8691_CR10","unstructured":"Salloway S, Gregg K, Black R, Grundman M, Sperling R. (2009) Cognitive and functional outcomes from a phase II trial of bapineuzumab in mild to moderate Alzheimer\u2019s disease. American Academy of Neurology Abs S32.002"},{"key":"8691_CR11","unstructured":"Sperling R, Salloway S, Fox N, Barackos J, Morris K, Francis G, Black R, Grundman M (2009) Risk factors and clinical course associated with vasogenic edema in a phase II trial of bapineuzumab. Presentation at: 16th Congress of the European Federation of Neurological Societies, Stockholm, Sweden. http:\/\/www.stevenderoover.be\/EFNS\/Presentations\/EFNS2012\/WC220\/ . Accessed 08 Sept 2012"},{"issue":"4","key":"8691_CR12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ana.23857","volume":"73","author":"F Piazza","year":"2013","unstructured":"Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, Nitrini R, Sakaguchi H, Brioschi M, Billo G et al (2013) Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for Amyloid-Modifying Therapies. Ann Neurol 73(4):449\u2013458","journal-title":"Ann Neurol"},{"key":"8691_CR13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","volume":"69","author":"S Ostrowitzki","year":"2012","unstructured":"Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX et al (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69:198\u2013207","journal-title":"Arch Neurol"},{"key":"8691_CR14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1742-2094-1-24","volume":"1","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1:24","journal-title":"J Neuroinflammation"},{"key":"8691_CR15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","volume":"25","author":"MM Racke","year":"2005","unstructured":"Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP et al (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25:629\u2013636","journal-title":"J Neurosci"},{"key":"8691_CR16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/489013a","volume":"489","author":"E Callaway","year":"2012","unstructured":"Callaway E (2012) Alzheimer\u2019s drugs take a new tack. Nature 489:13\u201314","journal-title":"Nature"},{"key":"8691_CR17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0531-5565(02)00029-3","volume":"37","author":"ME Weksler","year":"2002","unstructured":"Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 37:943\u2013948","journal-title":"Exp Gerontol"},{"key":"8691_CR18","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.neurobiolaging.2003.11.001","volume":"25","author":"S Mruthinti","year":"2004","unstructured":"Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, Schade RF (2004) Autoimmunity in Alzheimer\u2019s disease: Increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 25:1023\u20131032","journal-title":"Neurobiol Aging"},{"key":"8691_CR19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ana.21475","volume":"65","author":"A Kellner","year":"2009","unstructured":"Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M (2009) Autoantibodies against beta-amyloid are common in Alzheimer\u2019s disease and help control plaque burden. Ann Neurol 65:24\u201331","journal-title":"Ann Neurol"},{"key":"8691_CR20","doi-asserted-by":"crossref","first-page":"12145","DOI":"10.1073\/pnas.0904866106","volume":"106","author":"M Britschgi","year":"2009","unstructured":"Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH et al (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer\u2019s disease. Proc Natl Acad Sci U S A 106:12145\u201312150","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8691_CR21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.autrev.2008.03.004","volume":"7","author":"H Taguchi","year":"2008","unstructured":"Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Paul S (2008) Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev 7:391\u2013397","journal-title":"Autoimmun Rev"},{"key":"8691_CR22","doi-asserted-by":"crossref","first-page":"36724","DOI":"10.1074\/jbc.M806766200","volume":"283","author":"H Taguchi","year":"2008","unstructured":"Taguchi H, Planque S, Sapparapu G, Boivin S, Hara M, Nishiyama Y, Paul S (2008) Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J Biol Chem 283:36724\u201336733","journal-title":"J Biol Chem"},{"key":"8691_CR23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1006\/jmbi.1995.0580","volume":"253","author":"QS Gao","year":"1995","unstructured":"Gao QS, Sun M, Rees AR, Paul S (1995) Site-directed mutagenesis of proteolytic antibody light chain. J Mol Biol 253:658\u2013664","journal-title":"J Mol Biol"},{"key":"8691_CR24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1042\/BJ20051739","volume":"395","author":"PA Ramsland","year":"2006","unstructured":"Ramsland PA, Terzyan SS, Cloud G, Bourne CR, Farrugia W, Tribbick G, Geysen HM, Moomaw CR, Slaughter CA, Edmundson AB (2006) Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody. Biochem J 395:473\u2013481","journal-title":"Biochem J"},{"key":"8691_CR25","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/mt.2009.115","volume":"17","author":"Y Liu","year":"2009","unstructured":"Liu Y, Studzinski C, Beckett T, Guan H, Hersh MA, Murphy MP, Klein R, Hersh LB (2009) Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther 17:1381\u20131386","journal-title":"Mol Ther"},{"key":"8691_CR26","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1523\/JNEUROSCI.4792-03.2004","volume":"24","author":"N Iwata","year":"2004","unstructured":"Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP, Gerard C, Ozawa K, Saido TC (2004) Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci 24:991\u2013998","journal-title":"J Neurosci"},{"key":"8691_CR27","doi-asserted-by":"crossref","first-page":"8745","DOI":"10.1523\/JNEUROSCI.20-23-08745.2000","volume":"20","author":"A Mukherjee","year":"2000","unstructured":"Mukherjee A, Song E, Kihiko-Ehmann M, Goodman JP Jr, Pyrek JS, Estus S, Hersh LB (2000) Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci 20:8745\u20138749","journal-title":"J Neurosci"},{"issue":"Pt 2","key":"8691_CR28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1042\/0264-6021:3510509","volume":"351","author":"V Chesneau","year":"2000","unstructured":"Chesneau V, Vekrellis K, Rosner MR, Selkoe DJ (2000) Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization. Biochem J 351(Pt 2):509\u2013516","journal-title":"Biochem J"},{"key":"8691_CR29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3233\/JAD-2011-110230","volume":"27","author":"J Kou","year":"2011","unstructured":"Kou J, Kim HD, Pattanyak A, Song M, Lim J, Taguchi H, Paul S, Cirrito JR, Ponnazhagan S, Fukuchi K (2011) Anti-Abeta single-chain antibody brain delivery via AAV reduces amyloid load but may increase cerebral hemorrhages in an Alzheimer mouse model. J Alzheimers Dis 27:23\u201328","journal-title":"J Alzheimers Dis"},{"key":"8691_CR30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","volume":"108","author":"H Niwa","year":"1991","unstructured":"Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193\u2013199","journal-title":"Gene"},{"key":"8691_CR31","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1525-0016(03)00095-9","volume":"7","author":"D Grimm","year":"2003","unstructured":"Grimm D, Kay MA, Kleinschmidt JA (2003) Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 7:839\u2013850","journal-title":"Mol Ther"},{"key":"8691_CR32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1046-2023(02)00220-7","volume":"28","author":"S Zolotukhin","year":"2002","unstructured":"Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ Jr, Chiodo VA, Phillipsberg T, Muzyczka N, Hauswirth WW et al (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28:158\u2013167","journal-title":"Methods"},{"key":"8691_CR33","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.nbd.2006.04.012","volume":"23","author":"KI Fukuchi","year":"2006","unstructured":"Fukuchi KI, Tahara K, Kim HD, Maxwell JA, Lewis TL, Accavitti-Loper M, Kim H, Ponnazhagan S, Lalonde R (2006) Anti-A\u00df single chain antibody delivery via adeno-associated virus for treatment of Alzheimer\u2019s disease. Neurobiol Dis 23:502\u2013511","journal-title":"Neurobiol Dis"},{"key":"8691_CR34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/hmg\/ddh019","volume":"13","author":"JL Jankowsky","year":"2004","unstructured":"Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL et al (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159\u2013170","journal-title":"Hum Mol Genet"},{"key":"8691_CR35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1471-4159.2002.00889.x","volume":"81","author":"RB DeMattos","year":"2002","unstructured":"DeMattos RB, Bales KR, Parsadanian M, O\u2019Dell MA, Foss EM, Paul SM, Holtzman DM (2002) Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer\u2019s disease. J Neurochem 81:229\u2013236","journal-title":"J Neurochem"},{"key":"8691_CR36","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1523\/JNEUROSCI.5215-08.2009","volume":"29","author":"R Minkeviciene","year":"2009","unstructured":"Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A et al (2009) Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 29:3453\u20133462","journal-title":"J Neurosci"},{"key":"8691_CR37","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","volume":"69","author":"K Blennow","year":"2012","unstructured":"Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69:1002\u20131010","journal-title":"Arch Neurol"},{"key":"8691_CR38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA et al (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363\u2013372","journal-title":"Lancet Neurol"},{"key":"8691_CR39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","volume":"14","author":"I Ferrer","year":"2004","unstructured":"Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer\u2019s disease. Brain Pathol 14:11\u201320","journal-title":"Brain Pathol"},{"key":"8691_CR40","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.1078259","volume":"298","author":"M Pfeifer","year":"2002","unstructured":"Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M (2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298:1379","journal-title":"Science"},{"key":"8691_CR41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbd.2003.09.015","volume":"15","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D (2004) Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 15:11\u201320","journal-title":"Neurobiol Dis"},{"key":"8691_CR42","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","volume":"65","author":"JA Nicoll","year":"2006","unstructured":"Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D et al (2006) Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65:1040\u20131048","journal-title":"J Neuropathol Exp Neurol"},{"key":"8691_CR43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1742-4933-10-18","volume":"10","author":"J Moreth","year":"2013","unstructured":"Moreth J, Mavoungou C, Schindowski K (2013) Passive anti-amyloid immunotherapy in Alzheimer\u2019s disease: What are the most promising targets? Immun Ageing 10:18","journal-title":"Immun Ageing"},{"key":"8691_CR44","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1517\/14712598.2013.789856","volume":"13","author":"HO Tayeb","year":"2013","unstructured":"Tayeb HO, Murray ED, Price BH, Tarazi FI (2013) Bapineuzumab and solanezumab for Alzheimer\u2019s disease: Is the \u2018amyloid cascade hypothesis\u2019 still alive? Expert Opin Biol Ther 13:1075\u20131084","journal-title":"Expert Opin Biol Ther"},{"key":"8691_CR45","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","volume":"32","author":"O Adolfsson","year":"2012","unstructured":"Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK et al (2012) An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 32:9677\u20139689","journal-title":"J Neurosci"},{"key":"8691_CR46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2006.03.145","volume":"344","author":"KI Fukuchi","year":"2006","unstructured":"Fukuchi KI, Accavitti-Loper M, Kim HD, Tahara K, Cao Y, Lewis TL, Caughey RC, Kim H, Lalonde R (2006) Amelioration of amyloid load by anti-A[beta] single-chain antibody in Alzheimer mouse model. Biochem Biophys Res Commun 344:79\u201386","journal-title":"Biochem Biophys Res Commun"},{"key":"8691_CR47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneuroim.2012.01.008","volume":"244","author":"J Kou","year":"2012","unstructured":"Kou J, Song M, Pattanayak A, Lim J, Yang J, Cao D, Li L, Fukuchi K (2012) Combined treatment of A\u00df immunization with statin in a mouse model of Alzheimer\u2019s disease. J Neuroimmunol 244:70\u201383","journal-title":"J Neuroimmunol"},{"key":"8691_CR48","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ymthe.2005.11.015","volume":"13","author":"CN Cearley","year":"2006","unstructured":"Cearley CN, Wolfe JH (2006) Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13:528\u2013537","journal-title":"Mol Ther"},{"key":"8691_CR49","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1523\/JNEUROSCI.2185-07.2007","volume":"27","author":"CN Cearley","year":"2007","unstructured":"Cearley CN, Wolfe JH (2007) A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 27:9928\u20139940","journal-title":"J Neurosci"},{"key":"8691_CR50","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/gt.2010.179","volume":"18","author":"A Perren Van der","year":"2011","unstructured":"Van der Perren A, Toelen J, Carlon M, Van Den Haute C, Coun F, Heeman B, Reumers V, Vandenberghe LH, Wilson JM, Debyser Z et al (2011) Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2\/1, 2\/2, 2\/5, 2\/6.2, 2\/7, 2\/8 and 2\/9. Gene Ther 18:517\u2013527","journal-title":"Gene Ther"},{"key":"8691_CR51","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1089\/hum.2013.005","volume":"24","author":"L Samaranch","year":"2013","unstructured":"Samaranch L, Salegio EA, San SW, Kells AP, Bringas JR, Forsayeth J, Bankiewicz KS (2013) Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther 24:526\u2013532","journal-title":"Hum Gene Ther"},{"key":"8691_CR52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.pharmthera.2013.04.013","volume":"139","author":"GJ Harry","year":"2013","unstructured":"Harry GJ (2013) Microglia during development and aging. Pharmacol Ther 139:313\u2013326","journal-title":"Pharmacol Ther"},{"key":"8691_CR53","doi-asserted-by":"crossref","first-page":"11650","DOI":"10.1523\/JNEUROSCI.3024-08.2008","volume":"28","author":"S Jimenez","year":"2008","unstructured":"Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, Ruano D, Vizuete M, Gutierrez A, Vitorica J (2008) Inflammatory response in the hippocampus of PS1M146L\/APP751SL mouse model of Alzheimer\u2019s disease: Age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 28:11650\u201311661","journal-title":"J Neurosci"},{"key":"8691_CR54","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K et al (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916\u2013919","journal-title":"Nat Med"},{"key":"8691_CR55","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0196-9781(02)00261-9","volume":"23","author":"WA Banks","year":"2002","unstructured":"Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE (2002) Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer\u2019s disease. Peptides 23:2223\u20132226","journal-title":"Peptides"},{"key":"8691_CR56","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/srep01472","volume":"3","author":"N Iwata","year":"2013","unstructured":"Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, Higuchi M, Staufenbiel M, Muramatsu S, Saido TC (2013) Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep 3:1472","journal-title":"Sci Rep"},{"key":"8691_CR57","doi-asserted-by":"crossref","first-page":"e59626","DOI":"10.1371\/journal.pone.0059626","volume":"8","author":"N Carty","year":"2013","unstructured":"Carty N, Nash KR, Brownlow M, Cruite D, Wilcock D, Selenica ML, Lee DC, Gordon MN, Morgan D (2013) Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP\u2009+\u2009PS1 transgenic mice. PLoS ONE 8:e59626","journal-title":"PLoS ONE"},{"key":"8691_CR58","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jnr.10417","volume":"70","author":"HM Tucker","year":"2002","unstructured":"Tucker HM, Kihiko-Ehmann M, Estus S (2002) Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity and fibrillogenesis via plasminogen. J Neurosci Res 70:249\u2013255","journal-title":"J Neurosci Res"},{"key":"8691_CR59","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ymthe.2003.08.021","volume":"8","author":"H Fu","year":"2003","unstructured":"Fu H, Muenzer J, Samulski RJ, Breese G, Sifford J, Zeng X, McCarty DM (2003) Self-complementary adeno-associated virus serotype 2 vector: Global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther 8:911\u2013917","journal-title":"Mol Ther"},{"key":"8691_CR60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:59\u201365","journal-title":"Nat Biotechnol"},{"key":"8691_CR61","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","volume":"17","author":"S Duque","year":"2009","unstructured":"Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, Fyfe J, Moullier P, Colle MA, Barkats M (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17:1187\u20131196","journal-title":"Mol Ther"},{"key":"8691_CR62","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","volume":"19","author":"H Fu","year":"2011","unstructured":"Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM (2011) Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 19:1025\u20131033","journal-title":"Mol Ther"},{"key":"8691_CR63","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/mt.2010.299","volume":"19","author":"C Spampanato","year":"2011","unstructured":"Spampanato C, De LE, Dama P, Gargiulo A, Fraldi A, Sorrentino NC, Russo F, Nusco E, Auricchio A, Surace EM et al (2011) Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. Mol Ther 19:860\u2013869","journal-title":"Mol Ther"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-014-8691-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-014-8691-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-014-8691-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T09:55:46Z","timestamp":1565344546000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-014-8691-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,15]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["8691"],"URL":"https:\/\/doi.org\/10.1007\/s12035-014-8691-z","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,15]]}}}